Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Bryan Laffitte"'
Autor:
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte
Publikováno v:
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients
Externí odkaz:
https://doaj.org/article/f910e104a218414a82b33320fcf44859
Autor:
Zhihong Huang, Matthew S. Tremblay, Tom Y.-H. Wu, Qiang Ding, Xueshi Hao, Janine Baaten, Robert Hill, Bo Liu, Shelly Meeusen, Yefen Zou, Shanshan Yan, Yong Jia, Van Nguyen-Tran, Weijun Shen, Ganesh Bhat, Richard Glynne, Bryan Laffitte, Jing Li, Valentina Molteni, Yahu A. Liu
Publikováno v:
ACS Omega, Vol 4, Iss 2, Pp 3571-3581 (2019)
Externí odkaz:
https://doaj.org/article/5cf09ecffc814c04bc864f8859f4158a
Autor:
Hans E Hohmeier, Lu Zhang, Brandon Taylor, Samuel Stephens, Danhong Lu, Peter McNamara, Bryan Laffitte, Christopher B Newgard
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0224344 (2020)
A key event in the development of both major forms of diabetes is the loss of functional pancreatic islet β-cell mass. Strategies aimed at enhancing β-cell regeneration have long been pursued, but methods for reliably inducing human β-cell prolife
Externí odkaz:
https://doaj.org/article/260fd6716c5b4e5ba17b5989713cf9e9
Autor:
Tingting Mo, Yefen Zou, Weijun Shen, Zhihong Huang, Xiaoyue Zhang, Qihui Jin, Jing Li, Shifeng Pan, Michael Di Donato, Loren Jon, Andrew M. Schumacher, George Harb, Shanshan Yan, Anwesh Kamireddy, You-Qing Zhang, Tom Y.-H. Wu, Yong Jia, Xueshi Hao, Yahu A. Liu, Richard Glynne, Bryan Laffitte, Brandon Taylor, Peter McNamara, Qiang Ding, Wenqi Gao, Valentina Molteni, Badry Bursalaya, Lisa Deaton, Chun Li
Publikováno v:
ChemMedChem. 15:1562-1570
Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus. The mainstream treatment approach involves regulation of insulin levels; however, approaches intended to increase β-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d25eb2a68736314c37d5245dad02a1
https://doi.org/10.1002/cmdc.202000183
https://doi.org/10.1002/cmdc.202000183
Autor:
Bo Liu, Sukwon Ha, H. Michael Petrassi, Kate Jacobsen, George Harb, W. Perry Gordon, Bryan Laffitte, Thanh Lam, Qihui Jin, Yong Jia, Janine E. Baaten, Minhua Qiu, Robert Hill, Shelly Meeusen, Shanshan Yan, Badry Bursulaya, Valentina Molteni, Anwesh Kamireddy, Lisa Deaton, Jianfeng Pan, You-Qing Zhang, Loren Jon, Michael DiDonato, Yahu A. Liu, Shifeng Pan, Andrew M. Schumacher, Tingting Mo, Yefen Zou, Xiaoyue Zhang, Weijun Shen, Karyn Colman, Richard Glynne, Xueshi Hao, Peter McNamara, Vân Nguyen-Tran, Zhicheng Wang, Sheryll Espinola, Bao Nguyen, Tom Y.-H. Wu, Jing Li, Qiang Ding
Publikováno v:
Journal of Medicinal Chemistry. 63:2958-2973
Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β-cell proliferation could be one approach toward diabetes intervention. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222e5ae5085b8fd7b08c90167919a793
https://doi.org/10.1021/acs.jmedchem.9b01624
https://doi.org/10.1021/acs.jmedchem.9b01624
Autor:
Kim Fischer, Bryan Laffitte, Jason D. Jacintho, Christopher Baccei, Catherine Lee, Karin J. Stebbins, Alex R. Broadhead, Davorka Messmer, Lucia Correa, Daniel S. Lorrain, Peppi Prasit, Austin Chen, Nicholas Simon Stock, Yalda Bravo
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 29:503-508
We previously published on the design and synthesis of novel, potent and selective PPARα antagonists suitable for either i.p. or oral in vivo administration for the potential treatment of cancer. Described herein is SAR for a subsequent program, whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e1852f2be64898c0f9b88e9a60a368
https://doi.org/10.1016/j.bmcl.2018.12.045
https://doi.org/10.1016/j.bmcl.2018.12.045
Autor:
Bryan Laffitte, David Ollis
Publikováno v:
2005 Annual Conference Proceedings.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ef4228be3a9f39a305d4b2e84cb9dd8
https://doi.org/10.18260/1-2--14878
https://doi.org/10.18260/1-2--14878
Autor:
Sean B. Joseph, Paul Vincent Rucker, Peter McNamara, Michael Badman, Todd Groessl, Chianelli Donatella, Bo Liu, Alan Chu, Yugang Liu, Badry Bursulaya, H. Martin Seidel, Young Kim, John Nelson, Valentina Molteni, David C. Tully, David J Huang, Wendy Richmond, Andrew Phimister, Dingjiu Bao, Jane Wu, Thierry Schlama, Jason Roland, Eloy D. Hernandez, Bryan Laffitte, Jocelyn Zoll, Mahavir Prashad, Ignacio Sancho-Martinez, Robert Hill, Xiaodong Liu, James Schmeits
Publikováno v:
Journal of medicinal chemistry. 63(8)
Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects on multiple aspects of the disease. FXR agonists reduce lipid accum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::308b3ff9affec6142819020e4a0d2b6c
https://pubmed.ncbi.nlm.nih.gov/31940200
https://pubmed.ncbi.nlm.nih.gov/31940200
Autor:
Lu Zhang, Samuel B. Stephens, Hans E. Hohmeier, Brandon Taylor, Bryan Laffitte, Christopher B. Newgard, Peter McNamara
A key event in the development of both major forms of diabetes is the loss of functional pancreatic islet β-cell mass. Strategies aimed at enhancing β-cell regeneration have long been pursued, but methods for reliably inducing human β-cell prolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e523cdcf4728e2fdca88f760d38e531f
Autor:
Peter McNamara, Jocelyn Zoll, Lianxing Zheng, Shelly Meeusen, Young Kim, Glenn C. Federe, Lihao Chen, Eloy D. Hernandez, John R. Walker, Dingjiu Bao, Lloyd B. Klickstein, William F. Dietrich, Paul Vincent Rucker, Valentina Molteni, Bin Fang, Reginald Valdez, Sean B. Joseph, Bo Liu, James Schmeits, Claire Dubois, Chianelli Donatella, Michael Badman, David C. Tully, Bryan Laffitte, Jie Xu
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b079294bba158fc56bd23ecf7f7afe6
https://pubmed.ncbi.nlm.nih.gov/31388629
https://pubmed.ncbi.nlm.nih.gov/31388629